Compare Expedia Group Inc (EXPE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Incyte Corporation — how do they compare? Expedia Group Inc trades at $274.22 (market cap $32.42B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Expedia Group Inc pays a 0.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Incyte Corporation for 33 Days on average.
| EXPE | INCY | |
|---|---|---|
Market Cap | $32.42B | $22.85B |
Volume | 1,940,671 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $129.93 |
52-Week Low | $188.51 | $83.80 |
Typical Hold Time | 47 Days | 33 Days |
Enterprise Value | $30.98B | $18.35B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $270.13, up 4.35% today, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.76 surpassing the $5.22 forecast. Revenue growth is steady, reaching $14.73 billion in 2025, and the company maintains a high gross profit margin of 90.43%. However, recent news highlights competitive threats from AI agents, and the stock faces resistance near $275.
The outlook for EXPE is mixed; solid earnings growth and a consensus price target of $335.06 suggest upside potential, but investor sentiment is cautious due to AI disruption risks and a nearly even split between buy and hold ratings. Key risks include Meta's Muse AI agent potentially bypassing travel aggregators and ongoing layoffs impacting operational efficiency.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
